StockNews.AI
ATRA
StockNews.AI
213 days

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA

1. Pomerantz LLP investigates Atara for possible securities fraud. 2. Atara's stock dropped 40.5% following FDA's Complete Response Letter. 3. CRL related to issues at a third-party manufacturing facility. 4. Investors can join the class action against Atara. 5. The firm has a history of successful class-action litigation.

3m saved
Insight
Article

FAQ

Why Very Bearish?

The 40.5% stock drop indicates severe investor concern. Past examples show significant downturns from regulatory setbacks.

How important is it?

The article discusses legal investigations affecting Atara directly. Such cases can significantly impact stock value and investor sentiment.

Why Short Term?

Immediate effects from the stock drop and lawsuit may linger briefly. Regulatory issues usually impact price in coming months.

Related Companies

ATRA
Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Atara and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.[Click here for information about joining the class action]On January 16, 2025, Atara issued a press release announcing receipt of "a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the EBVALLOTM (tabelecleucel) Biologics License Application (BLA) as monotherapy treatment for adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one prior therapy including an anti-CD20 containing regimen." The Company stated that "[t]he CRL was solely related to observations as part of a standard pre-license inspection of a third-party manufacturing facility for EBVALLO."On this news, Atara's stock price fell 40.50% on January 16, 2025.The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.Attorney advertising. Prior results do not guarantee similar outcomes.SOURCE: Pomerantz LLP

Related News